Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist

[1] Sakurai T(1998)Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell 92 573-585

[2] Amemiya A(2007)The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness Nat Rev Neurosci. 8 171-181

[3] Ishii M(2017)The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468 J Pharmacol Exp Ther. 362 489-503

[4] Matsuzaki I(2018)The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases Front Mol Neurosci. 11 220-1078

[5] Chemelli RM(2020)Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders Expert Opin Drug Metab Toxicol. 16 1063-90

[6] Tanaka H(2013)Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders: rationale for development and current status CNS Drugs 27 83-155

[7] Sakurai T(2007)Promotion of sleep by targeting the orexin system in rats, dogs and humans Nat Med. 13 150-985

[8] Treiber A(2012)Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial Clin Pharmacol Ther. 91 975-356

[9] de Kanter R(2020)Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder Ann Neurol. 87 347-857

[10] Roch C(2019)Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration Eur Neuropsychopharmacol. 29 847-e2232

[1] Sakurai T(1998)Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell 92 573-585

[2] Amemiya A(2007)The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness Nat Rev Neurosci. 8 171-181

[3] Ishii M(2017)The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468 J Pharmacol Exp Ther. 362 489-503

[4] Matsuzaki I(2018)The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases Front Mol Neurosci. 11 220-1078

[5] Chemelli RM(2020)Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders Expert Opin Drug Metab Toxicol. 16 1063-90

[6] Tanaka H(2013)Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders: rationale for development and current status CNS Drugs 27 83-155

[7] Sakurai T(2007)Promotion of sleep by targeting the orexin system in rats, dogs and humans Nat Med. 13 150-985

[8] Treiber A(2012)Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial Clin Pharmacol Ther. 91 975-356

[9] de Kanter R(2020)Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder Ann Neurol. 87 347-857

[10] Roch C(2019)Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration Eur Neuropsychopharmacol. 29 847-e2232